# Tirzepatide

> Tirzepatide is a dual GIP/GLP-1 receptor agonist approved in some countries for type 2 diabetes and chronic weight management. Large randomized trials have reported substantial average body-weight reduction compared with placebo. It is administered by once-weekly subcutaneous injection with a gradual dose-escalation schedule. As with other incretin-based therapies, individual results vary and long-term studies continue to refine understanding of its effects.

- URL: https://www.lifeconverted.com/peptides/tirzepatide
- Also known as: LY3298176, Mounjaro, Zepbound
- Primary category: Weight Management
- Effectiveness rank: #2 in Weight Management
- Evidence level: Well studied
- Route: Subcutaneous
- Dose range: 2.5-15 mg
- Dose tiers: low 2.5 mg; moderate 7.5 mg; high 15 mg
- Half-life: Approximately 5 days, supporting once-weekly dosing
- Timing: Weekly · same day, any time
- Cycle: Continuous, ongoing use with titration per prescriber guidance on, Not typically cycled off; any discontinuation should be discussed with a prescriber off (Weight regain has been observed after discontinuation in published follow-up data.)
- Storage: Refrigerate at 2-8°C; pens may be stored at room temperature for limited periods per manufacturer labeling; protect from light and do not freeze.

## Mechanism of action

Tirzepatide activates both GIP and GLP-1 receptors, combining appetite-suppressing and gastric-emptying effects of GLP-1 signaling with additional GIP-receptor activity thought to enhance insulin sensitivity and further support weight reduction. The dual-agonist action is believed to produce greater metabolic effect than GLP-1 agonism alone, though the precise interplay of the two pathways in humans is still being studied.

## Reported benefits

- Associated with significant average body-weight reduction in clinical trials
- Improves glycemic control in type 2 diabetes
- May improve several cardiometabolic risk markers
- Once-weekly injection schedule

## Reported side effects

- Nausea, vomiting, diarrhea, and constipation, particularly during titration
- Decreased appetite
- Risk of gallbladder-related events
- Injection-site reactions
- Class-labeled theoretical thyroid C-cell tumor risk

## Common protocols

- Manufacturer-labeled titration schedule increasing dose every 4 weeks
- Once-weekly subcutaneous injection with site rotation

## Stacking notes

Combining with other GLP-1/GIP agents is not supported by evidence and may increase side-effect burden; any combination therapy should be supervised by a prescriber.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer